Search

Background: Upper limb impairment affects activity and participation in children with unilateral cerebral palsy (UCP). Pressure garment therapy (PGT) using compressive dynamic Lycra® garments is an innovative intervention proposed for the management of cerebral palsy consequences. The PROPENSIX study aims to evaluate the efficacy of a therapy using a Lycra® sleeve as compared to a placebo sleeve to improve bi-manual performance measured by the Assisting Hand Assessment (AHA) in children with unilateral cerebral palsy.Methods: The PROPENSIX trial is a multicenter, prospective, placebo-controlled, double-blinded, randomized study. One hundred children with UCP, aged from 5 to 10, are randomly assigned as soon as they are recruited in a 1:1 ratio to perform usual daily activities, especially activities involving bimanual performances, with Lycra® sleeve or placebo sleeve during 6 months. The primary endpoint is the change in bimanual performance from inclusion to 6 months, evaluated by AHA. The secondary endpoints evaluate changes from inclusion to 6 months in other dimensions of the International Classification of Functioning (ICF), upper limb movement capacity assessed by Quality of Upper Extremity Skill Test (QUEST), and health-related quality of life evaluated by Pediatric Quality of Life Inventory 3.0 Cerebral Palsy Module (PedsQLTM 3.0 CP Module) and in body structures and functions domain assessed by neuro-orthopedic examination and somatosensory evoked potentials (SEP).Discussion: The PROPENSIX study is the largest randomized controlled trial (RCT) aiming to evaluate the efficacy of a PGT using compressive dynamic Lycra® sleeve in UCP. Enhancement of children's bimanual performance at the end of the 6 months wear of the Lycra® sleeve should improve evidence regarding this type of treatment and expand discussion about their recommendation in clinical practice. Data from secondary outcomes assessments should bring interesting arguments to discuss the Lycra® sleeve action on mobility, tonus, and sensory impairments in children with unilateral cerebral palsy.Trial Registration: ClinicalTrials.gov NCT02086214 . Retrospectively registered on March 13, 2014 TRIAL STATUS: Study start data: December 2012. Recruitment status: completed. Primary completion date: April 2021. Estimated study completion date: December 2022. Protocol version 10 (date: February 2018). [ABSTRACT FROM AUTHOR]

Background: This study was conducted to assess the safety and adherence of the use of a PGT (Pressure Garment Therapy) Lycra® sleeve to treat upper limb unilateral cerebral palsy (UCP) in children., Methods: This study was conducted as a prospective, placebo-controlled, double-blinded, randomized monocenter study. Included in the study were 58 UCP children, 49 of whom were analyzed. 25 children (mean age 6.6 ± 1.6 years; 12 girls) were allocated to the active group vs. 24 (mean age 6.7 ± 1.6 years; 10 girls) in the placebo group. The intervention consisted of an active PGT Lycra® arm sleeve manufactured to generate a homogeneous pressure ranging from 15 to 25 mmHg. The placebo PGT Lycra® sleeve was manufactured to generate a homogeneous pressure under 7 mmHg. The time of wearing period was set at 3 h/day at minimum and 6 h/day at maximum, over the course of 6 months. The main outcome measures were safety outcomes including the number and intensity of Adverse Events of Special Interest (AESIs). AESIs were defined as adverse events imputable to compressive therapy and Lycra® wearing. Level of adherence was expressed in percentage of number of days when the sleeve was worn for at least 3 h per day compared to length of duration in days (start and end date of wearing period)., Results: Frequency of AESIs were very low and no different between groups (4.12 ± 11.32% vs. 1.83 ± 3.38%; p  = 0.504). There were no differences in adherence (91.86 ± 13.86% vs. 94.30 ± 9.95%; p  = 0.425)., Conclusion: The use of PGT Lycra® arm sleeve in children with UCP is safe and well-tolerated with a very good adherence. The low rate of AESIs is promising for further randomized clinical trials on efficacy., Competing Interests: YZ is CEO of Medical Z®. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Béghin, Mohammad, Fritot, Letellier, Masson, Zagamé, Donskoff, Toussaint-Thorin and Gottrand.)

Background: Quality of life is a subjective point of view of the patient. Its measurement is complex, but useful to personalize interventions and to evaluate the effect of care, particularly in physical medicine., Aim: To determine the psychometric properties of the Duke Health Profile (DHP) in neuromuscular disease. This instrument was chosen for its excellent acceptability and its ability to evaluate ten dimensions in a short administration., Design: Prospective multicentre study., Setting: Neuromuscular patients in centers in Reims, Dijon and Besancon., Population: Patients over 18 years with neuromuscular disorders., Methods: Successive inclusion between 2002 and 2005; DHP administration on two occasions, 15 days apart; collection of socio-demographic data. Statistical analyses using SAS SOFTWARE 9.3., Results: One hundred thirty-nine patients were included. The acceptability of the DHP was excellent. The disability dimension showed marked ceiling effect. Reliability was acceptable (Cronbach=0.54-0.73, except for the social health dimension [0.40], ICC=0.55-0.83). The anxiety and depression dimensions had discriminant properties in distinguishing patients with different functional status., Conclusion: The DHP is suitable and valid for patients with neuromuscular disease, with some reservations for the social health and disability dimensions., Clinical Rehabilitation Impact: This tool can be used in daily clinical practice and in research.